RxDoctor Payments Data

Edwin Avbuere, MD

Internal Medicine · Greensboro, NCNPI 1013019470

Payments from drug & device makers

$4,969in general payments, 2019–2025

Across 296 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$680
  • AstraZeneca$432
  • GSK$317
  • Novo Nordisk$299
  • Merck$287
  • AbbVie$250
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$4,86998%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,969 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,414
Medicare patients
164
Services billed
2,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide237$307,392
JardianceEmpagliflozin243$298,063
OzempicSemaglutide256$282,283
TrulicityDulaglutide99$148,906
LinzessLinaclotide195$134,768
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$119,676
EliquisApixaban88$114,767
JanuviaSitagliptin Phosphate89$114,280
FarxigaDapagliflozin Propanediol89$97,396
XareltoRivaroxaban86$75,325
SymbicortBudesonide/Formoterol Fumarate145$51,094
Tresiba Flextouch U-100Insulin Degludec85$46,055
Diclofenac Sodium456$40,191
EntrestoSacubitril/Valsartan26$38,283
MyrbetriqMirabegron36$30,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$680$456,298336 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$196$327,371287 claims
Novo NordiskOzempic$299$282,283256 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$432$162,743249 claims
AbbVieLinzess, Creon$250$162,016214 claims
MerckJanuvia, Janumet$287$141,403106 claims
GSKTrelegy Ellipta, Breo Ellipta$317$125,808145 claims
PfizerEliquis, Premarin$95$120,50699 claims
Johnson & JohnsonXarelto$110$75,32586 claims
NovartisEntresto$76$38,28326 claims
Astellas Pharma US IncMyrbetriq$124$30,46736 claims
Sumitomo Pharma America, Inc.Gemtesa$125$17,65313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →